Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The 12-week core study was designed to evaluate risk-benefit of three subcutaneous dose
regimens of ACZ885, added on to stable methotrexate (MTX) therapy (greater than or equal to
7.5 mg/week), compared to placebo in patients with active rheumatoid arthritis (RA). The
study investigated the magnitude of effect as well as onset of effect for the different dose
regimens.
The primary objective of the extension studies was to assess long-term safety and
tolerability of canakinumab (ACZ885) in patients with active RA. CACZ885A2201E1 evaluated
this objective in patients who had participated in the core study (CACZ885A2201) and
CACZ885A2201E2 did the same in patients who completed the first extension study.